Abstract
Background Brazil has a highly admixed population. Polygenic Risk Scores (PRS) have mostly been developed from European population studies, and their application to other populations is challenging. To assess the use of PRS for breast cancer (BC) risk in Brazil, we evaluated four PRSs in the Brazilian population.
Methods We analyzed a Brazilian cohort composed of 6,206 women with a history of breast cancer and 8,878 unphenotyped adults as controls. Genomic variants were imputed from exomes and scores were calculated for all samples.
Results After excluding individuals with known pathogenic or likely pathogenic variants in BRCA1, BRCA2, PALB2, PTEN, or TP53 genes, and first-degree relatives of the probands, 5,598 cases and 8,767 controls remained. Four PRS models were compared, and PRS3820 from Mavaddat et al. 2019 study showed the best performance, with an Odds Ratio (OR) of 1.43 per standard deviation increase (p-value: < 0.001) and an OR of 1.88 (p-value: < 0.001) for the top decile. PRS3820 also performed well for different ancestry groups: East Asian majority (OR 1.59, p-value 0.004), Non-European majority (OR 1.45, p-value: <0.001), and European majority (OR: 1.43, p-value: <0.001).
Conclusion Among different PRS, the PRS3820 performed better in the highly admixed Brazilian population. This will allow a more precise BC risk assessment of mutation-negative women in Brazil.
Competing Interest Statement
Flávia Eichemberger Rius, Danilo Viana, Júlia Salomão, Laila Gallo, Renata Freitas, Cláudia Bertolacini, Lucas Taniguti, Danilo Imparato, Flávia Antunes, Gabriel Sousa, Renan Achjian, Eric Fukuyama, Cleandra Gregório, Iuri Ventura, Juliana Gomes, Nathália Taniguti, and David Schlesinger are currently employed by Mendelics, or were employed at the time of the study. Rodrigo Guindalini acted as a consultant for AstraZeneca, Janssen Oncology, Roche/Genentech and Igenomix; received speaker honoraria from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Merck Sharpe & Dohme Brasil, Novartis, and Roche outside the submitted work; and has equity in Mendelics Análise Genômica. Olufunmilayo I. Olopade is co-founder at CancerIQ; serves as scientific advisor at Tempus; and has received research funding from Color Genomics and Roche/Genentech. José Eduardo Krieger, Yonglan Zheng, Dezheng Huo, Simone Maistro and Maria Aparecida Koike declare no competing interests.
Funding Statement
Maria Aparecida Azevedo Koike Folgueira received research support from Conselho Nacional de Desenvolvimento Científico e Tecnológico, Brazil (CNPq-308052/2022-6).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This work was approved by the Ethics Committee Comissão para análise de projeto de pesquisa of Hospital das Clínicas da FMUSP - CAPPesq under the CAAE number 70112423.3.0000.0068
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos